

Specimen Collected: 18-Dec-23 09:37

Autoimmune Epilepsy Panel, Serum Procedure	Received: 18-Dec-23 09:40 Result	Units	Report/Verified: 18-Dec-23 09:54 Reference Interval
Neuronal Antibody (Amphiphysin)	High Positive * i1		[Negative]
Purkinje Cell/Neuronal Nuclear IgG Scrn	PCCA Detected * f1 i2		[None Detected]
NMDA Receptor Ab IgG CBA-IFA, Serum	1:40 * f2 i3		[<1:10]
CASPR2 Ab IgG CBA-IFA Screen, Serum	Detected * t1 i4		[<1:10]
LG11 Ab IgG CBA-IFA Screen, Serum	Detected * t2 i5		[<1:10]
CV2 Ab IgG CBA-IFA Screen, Serum	Detected * t3 i6		[<1:100]
AMPA Receptor Ab IgG CBA-IFA Scrn, Serum	Detected * t4 i7		[<1:10]
GABA-BR Ab IgG CBA-IFA Scrn, Ser	Detected * t5 i8		[<1:10]
SOX1 Antibody, IgG by Immunoblot, Serum	High Positive * i9		[Negative]
DPPX Ab IgG CBA-IFA Screen, Serum	Detected * t6 i10		[<1:10]
GABA-AR Ab IgG CBA-IFA Screen, Serum	Detected * t7 i11		[<1:10]
mGluR1 Ab IgG CBA-IFA Screen, Serum	Detected * t8 i12		[<1:10]
Glutamic Acid Decarboxylase Antibody	10.0 # i13	IU/mL	[0.0-5.0]

Neuronal Nuclear Ab IgG, Immunoblot, Ser	Received: 18-Dec-23 09:40 Result	Units	Report/Verified: 18-Dec-23 09:54 Reference Interval
Neuronal Nuclear Ab (Hu) IgG, IB, Serum	Positive * i14		[Negative]
Neuronal Nuclear Ab (Ri) IgG, IB, Serum	Positive * i15		[Negative]
Neuronal Nuclear Ab (Yo) IgG, IB, Serum	Positive * i16		[Negative]
Neuronal Nuclear Ab (TR/DNER) IgG, IB	Positive * i17		[Negative]

Purkinje Cell Ab Titer, IgG Procedure	Received: 18-Dec-23 09:40 Result	Units	Report/Verified: 18-Dec-23 09:54 Reference Interval
Purkinje Cell Antibody Titer IgG	1:160 * i18		[<1:10]

AMPA Rptr Ab IgG Titer by CBA-IFA, Ser	Received: 18-Dec-23 09:40 Result	Units	Report/Verified: 18-Dec-23 09:55 Reference Interval
AMPA Receptor Ab IgG CBA-IFA Titer, Ser	1:320 * i19		[<1:10]

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H-High, i-Test Information, L-Low, t-Interpretive Text, @=Performing lab

Unless otherwise indicated, testing performed at:

ARUP Laboratories

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

ARUP Accession: 23-352-900116

Report Request ID: 18510360

Printed: 20-Dec-23 13:00

Page 1 of 10

Procedure	Result	Units	Reference Interval
CASPR2 Ab IgG Titer by CBA-IFA, Ser	Received: 18-Dec-23 09:40 Report/Verified: 18-Dec-23 09:55		
CASPR2 Ab IgG CBA-IFA Titer, Serum	1:40 * ⁱ²⁰		[<1:10]
CV2 Ab IgG Titer by CBA-IFA, Ser	Received: 18-Dec-23 09:40 Report/Verified: 18-Dec-23 09:55		
CV2 Ab IgG CBA-IFA Titer, Serum	1:1600 * ⁱ²¹		[<1:100]
DPPX Ab IgG Titer by CBA-IFA, Ser	Received: 18-Dec-23 09:40 Report/Verified: 18-Dec-23 09:55		
DPPX Ab IgG CBA-IFA Titer, Serum	1:80 * ⁱ²²		[<1:10]
GABA-A Receptor IgG CBA-IFA Titer, Serum	Received: 18-Dec-23 09:40 Report/Verified: 18-Dec-23 09:55		
GABA-AR Ab IgG CBA-IFA Titer, Serum	1:80 * ⁱ²³		[<1:10]
GABA-B Rptr Ab IgG Titer by CBA-IFA, Ser	Received: 18-Dec-23 09:40 Report/Verified: 18-Dec-23 09:55		
GABA-BR Ab IgG CBA-IFA Titer, Ser	1:160 * ⁱ²⁴		[<1:10]
LG11 Ab IgG Titer by CBA-IFA, Ser	Received: 18-Dec-23 09:40 Report/Verified: 18-Dec-23 09:55		
LG11 Ab IgG CBA-IFA Titer, Serum	1:320 * ⁱ²⁵		[<1:10]
mGluR1 Ab IgG CBA-IFA Titer, Serum	Received: 18-Dec-23 09:40 Report/Verified: 18-Dec-23 09:55		
mGluR1 Ab IgG CBA-IFA Titer, Serum	1:40 * ⁱ²⁶		[<1:10]

Interpretive Text

- t1: 18-Dec-23 09:37 (CASPR2 Ab IgG CBA-IFA Screen, Serum)
CASPR2 Antibody, IgG is detected. Titer results to follow.
- t2: 18-Dec-23 09:37 (LG11 Ab IgG CBA-IFA Screen, Serum)
LG11 Antibody, IgG is detected. Titer results to follow.
- t3: 18-Dec-23 09:37 (CV2 Ab IgG CBA-IFA Screen, Serum)
CV2 Antibody, IgG is detected. Titer results to follow. Additional charges apply.
- t4: 18-Dec-23 09:37 (AMPA Receptor Ab IgG CBA-IFA Scrn, Serum)
AMPA Antibody, IgG is detected. Titer results to follow.
- t5: 18-Dec-23 09:37 (GABA-BR Ab IgG CBA-IFA Scrn, Ser)
GABA-BR Antibody, IgG is detected. Titer results to follow.
- t6: 18-Dec-23 09:37 (DPPX Ab IgG CBA-IFA Screen, Serum)
DPPX Antibody, IgG is detected. Titer results to follow.
- t7: 18-Dec-23 09:37 (GABA-AR Ab IgG CBA-IFA Screen, Serum)
GABA-AR Antibody, IgG is detected. Titer results to follow.
- t8: 18-Dec-23 09:37 (mGluR1 Ab IgG CBA-IFA Screen, Serum)
mGluR1 Antibody, IgG is detected. Titer results to follow.

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H=High, i=Test Information, L=Low, t=Interpretive Text, @=Performing lab

Unless otherwise indicated, testing performed at:

ARUP Laboratories

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

ARUP Accession: 23-352-900116

Report Request ID: 18510360

Printed: 20-Dec-23 13:00

Page 2 of 10

Result Footnote

f1: Purkinje Cell/Neuronal Nuclear IgG Scrn

Antibodies detected, therefore IFA titer and Immunoblot testing to be performed.

f2: NMDA Receptor Ab IgG CBA-IFA, Serum

Antibodies to NMDA were detected; titer was performed at an additional charge.

The ExTINGUISH Trial (safety and efficacy of Inebilizumab in anti-NMDA receptor encephalitis, NCT04372615) is actively recruiting patients. To learn more, or to refer your patient, call 1-844-427-2465, email ExTINGUISH@hsc.utah.edu, or visit <https://neuronext.org/projects/nn111-extinguish>.

Test Information

i1: Neuronal Antibody (Amphiphysin)

INTERPRETIVE INFORMATION: Amphiphysin Antibody, IgG

Amphiphysin antibody is present in about 5 percent of patients with stiff-person syndrome and is found variably in other causes of paraneoplastic neurological syndrome (PNS). Amphiphysin antibody is mainly associated with small-cell lung cancer and breast tumors.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

i2: Purkinje Cell/Neuronal Nuclear IgG Scrn

INTERPRETIVE INFORMATION: Purkinje Cell/Neuronal Nuclear IgG Scrn

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

i3: NMDA Receptor Ab IgG CBA-IFA, Serum

INTERPRETIVE INFORMATION: NMDA Receptor Ab IgG CBA-IFA, Serum

NMDA receptor antibody is found in a subset of patients with autoimmune limbic encephalitis and may occur with or without associated tumor. Decreasing antibody levels may be associated with therapeutic response. In addition, positive results have been reported in patients with non-autoimmune phenotypes. A negative test result does not rule out a diagnosis of autoimmune limbic encephalitis. Results should be interpreted in correlation with the patient's clinical history and other laboratory findings. Serum testing should be paired with CSF testing for improved diagnostic sensitivity.

This indirect fluorescent antibody assay utilizes full-length GluN1 transfected cell lines for the detection and semiquantification of NMDA receptor IgG antibody.

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H=High, i=Test Information, L=Low, t=Interpretive Text, @=Performing lab

Unless otherwise indicated, testing performed at:**ARUP Laboratories**

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

ARUP Accession: 23-352-900116**Report Request ID:** 18510360**Printed:** 20-Dec-23 13:00

Page 3 of 10

Test Information

i3: NMDA Receptor Ab IgG CBA-IFA, Serum

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

i4: CASPR2 Ab IgG CBA-IFA Screen, Serum

INTERPRETIVE INFORMATION: CASPR2 Ab IgG CBA-IFA Screen, Serum

Contactin-associated protein-2 (CASPR2) IgG antibody may occur as part of the voltage-gated potassium channel (VGKC) complex antibodies.

The presence of CASPR2 IgG antibody is associated with a wide spectrum of clinical manifestations, including acquired neuromyotonia, limbic encephalitis, painful neuropathy, and Morvan syndrome. Tumors such as thymoma, small cell lung cancer, and other rarer tumors may occur. The full-spectrum of clinical disorders and tumors associated with the CASPR2 IgG antibody continues to be defined. Results should be interpreted in correlation with the patient's clinical history and other laboratory findings.

This indirect fluorescent antibody assay utilizes CASPR2 transfected cell lines for the detection and semiquantification of the CASPR2 IgG antibody.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

i5: LGI1 Ab IgG CBA-IFA Screen, Serum

INTERPRETIVE INFORMATION: LGI1 Ab IgG CBA-IFA Screen, Serum

Leucine-rich, glioma-inactivated 1 protein (LGI1) IgG antibody may occur as part of the voltage-gated potassium channel (VGKC) complex antibodies.

The presence of LGI1 IgG antibody is mainly associated with limbic encephalitis, hyponatremia, and myoclonic movements. LGI1 IgG antibody is rarely associated with tumors but may occur infrequently in Morvan syndrome, neuromyotonia, and idiopathic epilepsy. The full-spectrum of clinical disorders associated with the LGI1 IgG antibody continues to be defined. Results should be interpreted in correlation with the patient's clinical history and other laboratory findings.

This indirect fluorescent antibody assay utilizes LGI1 transfected cell lines for the detection and semiquantification of the LGI1 IgG antibody.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H-High, i-Test Information, L-Low, t-Interpretive Text, @=Performing lab

Unless otherwise indicated, testing performed at:

ARUP Laboratories

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

ARUP Accession: 23-352-900116

Report Request ID: 18510360

Printed: 20-Dec-23 13:00

Page 4 of 10

Test Information

i5: LGI1 Ab IgG CBA-IFA Screen, Serum

Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

i6: CV2 Ab IgG CBA-IFA Screen, Serum

INTERPRETIVE INFORMATION: CV2 Ab IgG CBA-IFA Screen, Serum

CV2 antibodies aid in discriminating between chronic paraneoplastic neurological disorder (PND) and other inflammatory disorders of the nervous system. Anti-CV2 is associated with small-cell lung cancer and thymoma. A negative test result does not rule out a diagnosis of autoimmune neurologic disease. Results should be interpreted in correlation with the patient's clinical history and other laboratory findings.

This indirect fluorescent antibody assay utilizes CV2 transfected cell lines for the detection and semiquantification of the CV2 IgG antibody.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

i7: AMPA Receptor Ab IgG CBA-IFA Scrn, Serum

INTERPRETIVE INFORMATION: AMPA Receptor Ab IgG CBA-IFA Scrn,
Serum

Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPA) antibody is found in a subset of patients with autoimmune limbic encephalitis and may occur with or without associated tumor. Decreasing antibody levels may be associated with therapeutic response. A negative test result does not rule out a diagnosis of autoimmune encephalitis. Results should be interpreted in correlation with the patient's clinical history and other laboratory findings.

This indirect fluorescent antibody assay utilizes AMPAR transfected cell lines for the detection and semiquantification of AMPAR IgG antibody.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

i8: GABA-BR Ab IgG CBA-IFA Scrn, Ser

INTERPRETIVE INFORMATION: GABA-BR Ab IgG CBA-IFA Scrn, Ser

Gamma-amino butyric acid receptor, type B (GABA-BR) antibody is found in a subset of patients with autoimmune epilepsy and other autoimmune neurologic phenotypes; it may occur with or without associated tumor. Decreasing antibody levels may be associated with therapeutic response. A negative test result does not rule out a diagnosis of autoimmune neurologic disease. Results should be interpreted in correlation with the patient's clinical history and other laboratory findings.

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H-High, i-Test Information, L-Low, t-Interpretive Text, @=Performing lab

Unless otherwise indicated, testing performed at:

ARUP Laboratories

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

ARUP Accession: 23-352-900116

Report Request ID: 18510360

Printed: 20-Dec-23 13:00

Page 5 of 10

Test Information

i8: GABA-BR Ab IgG CBA-IFA Scrn, Ser

This indirect fluorescent antibody assay utilizes GABA-BR transfected cell lines for the detection and semiquantification of GABA-BR IgG antibody.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

i9: SOX1 Antibody, IgG by Immunoblot, Serum

INTERPRETIVE INFORMATION: SOX1 Antibody, IgG by Immunoblot,
Serum

SOX1 antibody is detected in patients with Lambert-Eaton myasthenic syndrome (LEMS) and in patients with paraneoplastic cerebellar degeneration (PCD), paraneoplastic and nonparaneoplastic neuropathy. SOX1 antibody is associated with small cell lung cancer. A negative test result does not rule out a diagnosis of LEMS or other causes of paraneoplastic neurological syndrome.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

i10: DPPX Ab IgG CBA-IFA Screen, Serum

INTERPRETIVE INFORMATION: DPPX Ab IgG CBA-IFA Screen, Serum

DPPX antibody is found in a subset of patients with autoimmune encephalitis, and is often associated with prodromal gastrointestinal symptoms and unintentional weight loss. It may occur with or without associated tumor. Decreasing antibody levels may be associated with therapeutic response. A negative test result does not rule out a diagnosis of autoimmune neurologic disease. Results should be interpreted in correlation with the patient's clinical history and other laboratory findings.

This indirect fluorescent antibody assay utilizes DPPX transfected cells for the detection and semiquantification of the DPPX IgG antibody.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

i11: GABA-AR Ab IgG CBA-IFA Screen, Serum

INTERPRETIVE INFORMATION: GABA-AR Ab IgG CBA-IFA Screen,
Serum

Gamma-aminobutyric acid receptor, type A (GABA-AR) antibody is found in a subset of patients with autoimmune encephalitis or autoimmune epilepsy and may occur with or without associated tumor. A negative test result does not rule out a diagnosis of

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H-High, i-Test Information, L-Low, t-Interpretive Text, @=Performing lab

Unless otherwise indicated, testing performed at:

ARUP Laboratories

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

ARUP Accession: 23-352-900116

Report Request ID: 18510360

Printed: 20-Dec-23 13:00

Page 6 of 10

Test Information

i11: GABA-AR Ab IgG CBA-IFA Screen, Serum
autoimmune limbic encephalitis or autoimmune epilepsy. Interpretation of any antineural antibody test requires clinical correlation.

This indirect fluorescent antibody assay utilizes GABA-AR transfected cell lines for detection and semi-quantification of GABA-AR IgG antibody.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

i12: mGluR1 Ab IgG CBA-IFA Screen, Serum
INTERPRETIVE INFORMATION: mGluR1 Ab IgG CBA-IFA Screen,
Serum

Metabotropic glutamate receptor 1 (mGluR1) antibody is found in a subset of patients with autoimmune cerebellar ataxia or autoimmune encephalitis and may occur with or without associated tumor. A negative test result does not rule out a diagnosis of autoimmune cerebellar ataxia or limbic encephalitis. Interpretation of any antineural antibody test requires clinical correlation.

This indirect fluorescent antibody assay utilizes mGluR1 transfected cell lines for detection and semi-quantification of mGluR1 IgG antibody.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

i13: Glutamic Acid Decarboxylase Antibody
INTERPRETIVE INFORMATION: Glutamic Acid Decarboxylase Antibody

A value greater than 5.0 IU/mL is considered positive for Glutamic Acid Decarboxylase Antibody (GAD Ab). This assay is intended for the semi-quantitative determination of the GAD Ab in human serum. Results should be interpreted within the context of clinical symptoms.

i14: Neuronal Nuclear Ab (Hu) IgG, IB, Serum
INTERPRETIVE INFORMATION: Neuronal Nuclear Ab IgG,
Immunoblot, Ser

This test detects IgG antineuronal antibodies to Hu, Ri, Yo and Tr (DNER) antigens.

Antineuronal antibodies serve as markers that aid in discriminating between a true paraneoplastic neurological disorder (PND) and other inflammatory disorders of the nervous system. Anti-Hu (antineuronal nuclear antibody, type I) is associated with small-cell lung cancer. Anti-Ri (antineuronal nuclear antibody, type II) is associated with neuroblastoma in children and with fallopian tube and breast cancer

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H-High, i-Test Information, L-Low, t-Interpretive Text, @=Performing lab

Unless otherwise indicated, testing performed at:

ARUP Laboratories

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

ARUP Accession: 23-352-900116

Report Request ID: 18510360

Printed: 20-Dec-23 13:00

Page 7 of 10

Test Information

i14: Neuronal Nuclear Ab (Hu) IgG, IB, Serum

in adults. Anti-Yo (anti-Purkinje cell cytoplasmic antibody) is associated with ovarian and breast cancer. Anti-Tr(DNER) is associated with Hodgkin's lymphoma.

The presence of one or more of these antineuronal antibodies supports a clinical diagnosis of PND and should lead to a focused search for the underlying neoplasm.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

i15: Neuronal Nuclear Ab (Ri) IgG, IB, Serum

INTERPRETIVE INFORMATION: Neuronal Nuclear Ab (Ri) IgG, IB, Serum

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

i16: Neuronal Nuclear Ab (Yo) IgG, IB, Serum

INTERPRETIVE INFORMATION: Neuronal Nuclear Ab (Yo) IgG, IB, Serum

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

i17: Neuronal Nuclear Ab (TR/DNER) IgG, IB

INTERPRETIVE INFORMATION: Neuronal Nuclear Ab (TR/DNER) IgG, IB

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

i18: Purkinje Cell Antibody Titer IgG

INTERPRETIVE INFORMATION: Purkinje Cell Ab Titer, IgG

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

i19: AMPA Receptor Ab IgG CBA-IFA Titer, Ser

INTERPRETIVE INFORMATION: AMPA Receptor Ab IgG CBA-IFA Titer, Ser

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H-High, i-Test Information, L-Low, t-Interpretive Text, @=Performing lab

Unless otherwise indicated, testing performed at:

ARUP Laboratories

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

ARUP Accession: 23-352-900116

Report Request ID: 18510360

Printed: 20-Dec-23 13:00

Page 8 of 10

Test Information

i19: AMPA Receptor Ab IgG CBA-IFA Titer, Ser Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

i20: CASPR2 Ab IgG CBA-IFA Titer, Serum
INTERPRETIVE INFORMATION: CASPR2 Ab IgG CBA-IFA Titer, Serum

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

i21: CV2 Ab IgG CBA-IFA Titer, Serum
INTERPRETIVE INFORMATION: CV2 Ab IgG CBA-IFA Titer, Serum

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

i22: DPPX Ab IgG CBA-IFA Titer, Serum
INTERPRETIVE INFORMATION: DPPX Ab IgG CBA-IFA Titer, Serum

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

i23: GABA-AR Ab IgG CBA-IFA Titer, Serum
INTERPRETIVE INFORMATION: GABA-AR Ab IgG CBA-IFA Titer, Serum

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

i24: GABA-BR Ab IgG CBA-IFA Titer, Ser
INTERPRETIVE INFORMATION: GABA-BR Ab IgG CBA-IFA Titer, Ser

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

i25: LGI1 Ab IgG CBA-IFA Titer, Serum
INTERPRETIVE INFORMATION: LGI1 Ab IgG CBA-IFA Titer, Serum

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H-High, i-Test Information, L-Low, t-Interpretive Text, @=Performing lab

Unless otherwise indicated, testing performed at:

ARUP Laboratories

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

ARUP Accession: 23-352-900116

Report Request ID: 18510360

Printed: 20-Dec-23 13:00

Page 9 of 10

Test Information

i26: mGluR1 Ab IgG CBA-IFA Titer, Serum

INTERPRETIVE INFORMATION: mGluR1 Ab IgG CBA-IFA Titer, Serum

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H=High, i=Test Information, L=Low, t=Interpretive Text, @=Performing lab

Unless otherwise indicated, testing performed at:

ARUP Laboratories

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

ARUP Accession: 23-352-900116

Report Request ID: 18510360

Printed: 20-Dec-23 13:00